Biosignal compounds much more effective

Thursday, 24 January, 2008

Results from UK testing show Biosignal Ltd compounds have substantially outperformed the industry standard product glutaraldehyde against harmful sulphur reducing bacteria (SRB).

Final results of the second round of testing by Commercial Microbiology Ltd found that Biosignal compounds substantially outperformed glutaraldehyde even with lower concentrations of the Biosignal product. Cultures used were taken from a seawater injection system on a North Sea production platform.

The product is also relatively benign compared to glutaraldehyde and other biocides which are hazardous materials, with health, safety and environment risks.

This round included testing of different concentrations and, for the first time, re-circulating rather than continuously adding Biosignal compounds — the results of which showed that these re-circulated compounds responded with unexpectedly high efficacy.

This ability — to maintain activity when recycled — could significantly expand the potential applications of the compounds into areas where chemical treatment is currently not economically feasible.

Biosignal compounds do not work like traditional biocides that aggressively kill microorganisms. Biosignal compounds block communications between bacteria and this stops bacterial biofilms forming.

The company is a specialist oil and gas industry commercial testing company. The company is highly respected in the oil industry for providing specialist microbiological services for onshore and offshore operations. Trials by the company are ongoing to further optimise Biosignal products.

For further information, visit Commercial Microbiology.

Related News

Blood-based biomarker can detect sleep deprivation

The biomarker detected whether individuals had been awake for 24 hours with a 99.2% probability...

Epigenetic signature helps to diagnose rare breast tumour

The current way of diagnosing phyllodes tumours is to analyse their cellular features under a...

New instrument measures cardiovascular disease biomarkers

CVD-21 enables a 'liquid cardiovascular biopsy' for quantification of multiple...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd